[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Masdeu, 2011 - Google Patents

Neuroimaging in psychiatric disorders

Masdeu, 2011

View HTML
Document ID
8437742295941809509
Author
Masdeu J
Publication year
Publication venue
Neurotherapeutics

External Links

Snippet

In psychiatry, neuroimaging facilitates the diagnosis of psychiatric disorders and the development of new medications. It is used to detect structural lesions causing psychosis and to differentiate depression from neurodegenerative disorders or brain tumors …
Continue reading at www.sciencedirect.com (HTML) (other versions)

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0493Steroids, e.g. cholesterol, testosterone
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms

Similar Documents

Publication Publication Date Title
Masdeu Neuroimaging in psychiatric disorders
Parsey et al. Lower serotonin transporter binding potential in the human brain during major depressive episodes
Anand et al. Striatal dopamine transporter availability in unmedicated bipolar disorder
Tiger et al. A randomized placebo-controlled PET study of ketamine´ s effect on serotonin1B receptor binding in patients with SSRI-resistant depression
Meyer et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C] DASB positron emission tomography study
Drzezga et al. Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden
Yanai et al. The physiological and pathophysiological roles of neuronal histamine: an insight from human positron emission tomography studies
Cannon et al. Serotonin transporter binding in bipolar disorder assessed using [11C] DASB and positron emission tomography
Ballard et al. Neural correlates of suicidal ideation and its reduction in depression
Cervenka et al. Associations between dopamine D2-receptor binding and cognitive performance indicate functional compartmentalization of the human striatum
Zubieta et al. High vesicular monoamine transporter binding in asymptomatic bipolar I disorder: sex differences and cognitive correlates
Yeh et al. Availability of dopamine and serotonin transporters in opioid-dependent users—a two-isotope SPECT study
Zink et al. Association of missense mutation in FOLH1 with decreased NAAG levels and impaired working memory circuitry and cognition
Mattioli et al. Cuneus/precuneus as a central hub for brain functional connectivity of mild cognitive impairment in idiopathic REM sleep behavior patients
Abou-Saleh Neuroimaging in psychiatry: an update
Plavén-Sigray et al. Thalamic dopamine D2-receptor availability in schizophrenia: a study on antipsychotic-naive patients with first-episode psychosis and a meta-analysis
Rodríguez-Chinchilla et al. [18 F]-DPA-714 PET as a specific in vivo marker of early microglial activation in a rat model of progressive dopaminergic degeneration
Tseng et al. In vivo human brain expression of histone deacetylases in bipolar disorder
Boscutti et al. PET Radioligands for imaging of the PDE10A in human: current status
Asai et al. GABAA/Benzodiazepine receptor binding in patients with schizophrenia using [11C] Ro15-4513, a radioligand with relatively high affinity for α5 subunit
Shin et al. The relationship between frontostriatal connectivity and striatal dopamine function in schizophrenia: An 18F-DOPA PET and Diffusion tensor imaging study in treatment responsive and resistant patients
Borg et al. Contribution of non-genetic factors to dopamine and serotonin receptor availability in the adult human brain
Sharma et al. SPECT neuroimaging in translational research of CNS disorders
Song et al. Amphetamine-induced dopamine release and impulsivity in Parkinson’s disease
Viviani et al. Effects of amisulpride on human resting cerebral perfusion